Opatanol

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification[1] issued on	Commission Decision Issued[2] / amended on	Product Information affected[3]	Summary
IB/0046	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	23/08/2022		SmPC	To update section 6.5 of the SmPC, to delete the term 'DROP-TAINER'.
PSUSA/2211/ 202104	Periodic Safety Update EU Single assessment - olopatadine	02/12/2021	n/a		PRAC Recommendation - maintenance

[1] Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.
[2] A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
[3] SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

IAIN/0045/G	This was an application for a group of variations. A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing	05/10/2021	18/11/2021	Annex II and PL	
IB/0042	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	10/11/2020	18/11/2021	SmPC, Annex II, Labelling and PL	
IAIN/0043/G	This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	07/10/2020	n/a		
IA/0041	B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test	16/01/2020	n/a		

	procedure				
IA/0040/G	This was an application for a group of variations. B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier	25/07/2019	n/a		
PSUSA/2211/ 201804	Periodic Safety Update EU Single assessment - olopatadine	17/01/2019	n/a		PRAC Recommendation - maintenance

IA/0039	A.7 - Administrative change - Deletion of manufacturing sites	14/12/2018	n/a		
IA/0038	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	05/10/2018	13/09/2019	SmPC, Annex II, Labelling and PL	
T/0036	Transfer of Marketing Authorisation	20/03/2018	19/04/2018	SmPC, Labelling and PL	
II/0035/G	This was an application for a group of variations. B.I.a.1.b - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a manufacturer of the AS supported by an ASMF B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.c - Change in the specification parameters	01/02/2018	n/a		

	and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure				
T/0034	Transfer of Marketing Authorisation	06/04/2017	24/04/2017	SmPC, Labelling and PL	
IA/0033	A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient	13/04/2016	n/a		
II/0032	B.II.c.1.d - Change in the specification parameters and/or limits of an excipient - Change outside the approved specifications limits range	14/01/2016	n/a		
PSUSA/2211/ 201504	Periodic Safety Update EU Single assessment - olopatadine	14/01/2016	n/a		PRAC Recommendation - maintenance
IG/0452	C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location	28/07/2014	n/a		
IB/0029/G	This was an application for a group of variations.	01/07/2014	n/a		

	B.II.b.1.f - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the FP - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile medicinal products (including those that are aseptically manufactured) excluding biological/ immunological medicinal products B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation				
N/0028	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	09/01/2014	03/03/2014	PL	
II/0027/G	This was an application for a group of variations. Update of section 4.8 of the SmPC to add that cases of corneal calcification have been reported very rarely in association with the use of phosphate containing eye drops. The package leaflet has been updated accordingly. Furthermore, sections 4.2, 4.4, 4.6 and 5.3 of the Summary of Product Characteristics (SmPC) and corresponding relevant sections of the Package Leaflet (PL) have been updated in accordance with the European SmPC Guideline and the latest QRD template, based on the review of relevant published	24/10/2013	03/03/2014	SmPC, Annex II, Labelling and PL	In the context of an assessment of the use of phosphate buffers in medicinal products given as eye drops and whether these can cause corneal calcification (build-up of calcium deposits in the cornea, the clear layer at the front of the eye), the CHMP examined information from the manufacturers on 655 different eye drop products, of which 236 contained phosphate. It also looked at reports of corneal calcification in patients using phosphate-containing eye drops, at published studies, and at estimates of how widely phosphate-containing eye drops are used. The evidence did not warrant a restriction on the use of phosphate buffers in eye drops, which might lead to patients being unable to obtain suitable treatments.

	literature. The product information has also been updated to align it with the recommendations included in the European SmPC Guideline and latest QRD template. C.I.3.a - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Implementation of wording agreed by the competent authority C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data				However, in view of the available data regarding cases of corneal calcification and in order to make prescribers and patients aware of the issue, relevant information is included in section 4.8 of the SmPC and section 4 of the PL. Based on the evaluation of the currently available data and the scientific discussion within the Committee, the CHMP considered that the benefits of the phosphate-containing eye drop medicines authorised in the EU continue to outweigh their risks, and therefore recommended that they can continue to be used. Furthermore, sections 4.2, 4.4, 4.6 and 5.3 of the Summary of Product Characteristics (SmPC) and corresponding relevant sections of the Package Leaflet (PL) have been updated based on the review of published literature as well as in accordance with the European SmPC Guideline and the latest QRD template.
IB/0024	B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)	21/08/2013	n/a		
IG/0324	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	22/07/2013	n/a		
N/0025	Update of the local representatives contact details in the package leaflet and inclusion of an additional local representative of the Marketing Authorisation Holder for the new Member State. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	02/07/2013	03/03/2014	PL	Update of the local representatives contact details in the package leaflet and inclusion of an additional local representative of the Marketing Authorisation Holder for Croatia.

IB/0022/G	This was an application for a group of variations. B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.d.z - Stability of AS - Other variation	14/05/2013	n/a		
IG/0274	A.1 - Administrative change - Change in the name and/or address of the MAH	19/03/2013	03/03/2014	SmPC, Labelling and PL	
IB/0018	B.II.b.3.z - Change in the manufacturing process of the finished product - Other variation	23/01/2012	n/a		
WS/0075	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. To replace the current resin which is used for the closures for the drop-trainer packaging system, with two new resins.	20/01/2011	20/01/2011		

	B.II.e.1.a.3 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Sterile medicinal products and biological/immunological medicinal products				
N/0017	Update of the contact details of the local representatives in Czech Republique, Finland, Iceland and Slovakia. The MAH also took the opportunity to add the European Medicines Agency's website address at the end of the Package Leaflet. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	24/09/2010	n/a	PL	
II/0016	To update ASMF for olopatadine hydrochloride following minor changes in the manufacturing process of the drug substance. Change(s) to the manufacturing process for the active substance	18/02/2010	11/03/2010		
II/0015	An alternate primary packaging for the active substance. Update of or change(s) to the pharmaceutical documentation	23/04/2009	27/04/2009		
IA/0014	IA_04_Change in name and/or address of a manuf. of the active substance (no Ph. Eur. cert. avail.)	16/02/2009	n/a		
N/0013	Update of the list of the local representatives in	14/01/2009	n/a	Labelling and	

	section 6 of the Package Leaflet and translation of INN into Bulgarian and Braille in the Bulgarian Labelling. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)			PL	
II/0012	Change to the site for ethylene oxide sterilisation of the primary packaging for Opatanol eye drops. Quality changes	15/11/2007	22/11/2007		
II/0011	Update of section 4.8 of the SPC (upon request of the CHMP following assessment of the renewal) based on a safety analysis including data from clinical studies which have been completed after the granting of the marketing authorisation. Section 4.8 of the SPC was also amended to include 'eye irritation' as requested by CHMP following asssement of PSUR6 covering the period from May 1st 2005 to April 30th 2006 and to reflect MedDRA terminology. Section 4 of the Package Leaflet (PL) has been changed accordingly. Update of Summary of Product Characteristics and Package Leaflet	19/07/2007	21/08/2007	SmPC and PL	The CHMP reviewed the safety analysis performed by the MAH that included data from clinical studies which have been completed after the initial marketing authorisation. The review of the section 4.8 of the SPC demonstrated that frequencies have changed from 'uncommon' to 'common' for dry eye, headache, dry nose and from 'very rare' to 'uncommon' for blurred vision and rhinitis. Additionally, a number of new ocular adverse reactions (e.g. eye irritation) and systemic reactions (e.g. skin reactions, dysgueusia, hypoesthesia, dyspnoea, somnolence, swelling face, nausea, malaise) were considered relevant to the inclusion in section 4.8 of the SPC.
R/0009	Renewal of the marketing authorisation.	22/03/2007	22/05/2007	SmPC, Annex II, Labelling and PL	Based on the CHMP review of the available information and on the basis of a re-evaluation of the benefit risk balance, the CHMP is of the opinion that the quality, safety and efficacy of this medicinal product continues to be

					adequately and sufficiently demonstrated and therefore considered that the benefit/risk profile of Opatanol continues to be favourable. Based on the CHMP review of the available information and on the basis of a re-evaluation of the benefit risk balance, the CHMP is of the opinion that the quality, safety and efficacy of this medicinal product continues to be adequately and sufficiently demonstrated and therefore considered that the benefit/risk profile of Opatanol continues to be favourable.
N/0010	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	16/02/2007	n/a	PL	
IB/0008	IB_38_c_Change in test procedure of finished product - other changes	19/01/2007	n/a		
IB/0007	IB_38_c_Change in test procedure of finished product - other changes	29/11/2006	n/a		
IB/0006	IB_38_c_Change in test procedure of finished product - other changes	29/11/2006	n/a		
IB/0005	IB_11_c_Change in batch size of active substance or intermediate - more than 10-fold	07/07/2005	n/a		
N/0003	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	15/11/2004	n/a	PL	

N/0002	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	13/05/2004	n/a	PL	
I/0001	01_Change in or addition of manufacturing site(s) for part or all of the manufacturing process	03/03/2003	09/04/2003	Annex II and PL	